These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 32763660)
21. Hematological changes in patients with COVID‑19 (Review). Ye J; Jiao Y; Zhang Y; Li Z; Zeng X; Deng H; Yang M Mol Med Rep; 2020 Dec; 22(6):4485-4491. PubMed ID: 33173966 [TBL] [Abstract][Full Text] [Related]
22. Emerging cardiological issues during the COVID-19 pandemic. Everaert BR; Muylle J; Bartholomeus Twickler T Eur J Clin Invest; 2020 Jul; 50(7):e13270. PubMed ID: 32415992 [No Abstract] [Full Text] [Related]
23. Prohemostatic and antithrombin activities of Ankaferd hemostat are linked to fibrinogen gamma chain and prothrombin by functional proteomic analyses. Ozel-Demiralp D; Igci N; Ayhan B; Egin Y; Haznedaroglu IC; Akar N Clin Appl Thromb Hemost; 2012 Nov; 18(6):604-10. PubMed ID: 22327821 [TBL] [Abstract][Full Text] [Related]
24. Coagulopathy and thromboembolic events in patients with SARS-CoV-2 infection: pathogenesis and management strategies. Allegra A; Innao V; Allegra AG; Musolino C Ann Hematol; 2020 Sep; 99(9):1953-1965. PubMed ID: 32671455 [TBL] [Abstract][Full Text] [Related]
25. May IL-17 have a role in COVID-19 infection? Megna M; Napolitano M; Fabbrocini G Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777 [No Abstract] [Full Text] [Related]
26. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Spyropoulos AC; Levy JH; Ageno W; Connors JM; Hunt BJ; Iba T; Levi M; Samama CM; Thachil J; Giannis D; Douketis JD; J Thromb Haemost; 2020 Aug; 18(8):1859-1865. PubMed ID: 32459046 [No Abstract] [Full Text] [Related]
27. Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper). Ciftciler R; Ciftciler AE; Malkan UY; Haznedaroglu IC SAGE Open Med; 2020; 8():2050312120907811. PubMed ID: 32110403 [TBL] [Abstract][Full Text] [Related]
28. Left ventricular dysfunction in COVID-19: A diagnostic issue. Jacquet-Lagrèze M; Riad Z; Hugon-Vallet E; Ferraris A; Fellahi JL Anaesth Crit Care Pain Med; 2020 Jun; 39(3):393-394. PubMed ID: 32562808 [No Abstract] [Full Text] [Related]
29. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Caron P Ann Endocrinol (Paris); 2020 Oct; 81(5):507-510. PubMed ID: 32950466 [TBL] [Abstract][Full Text] [Related]
30. Ankaferd hemostat: from molecules to medicine. Çiftçiler R; Haznedaroglu İC Turk J Med Sci; 2020 Nov; 50(SI-2):1739-1750. PubMed ID: 32283900 [TBL] [Abstract][Full Text] [Related]
31. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Serrano-Castro PJ; Estivill-Torrús G; Cabezudo-García P; Reyes-Bueno JA; Ciano Petersen N; Aguilar-Castillo MJ; Suárez-Pérez J; Jiménez-Hernández MD; Moya-Molina MÁ; Oliver-Martos B; Arrabal-Gómez C; Rodríguez de Fonseca F Neurologia (Engl Ed); 2020 May; 35(4):245-251. PubMed ID: 32364119 [TBL] [Abstract][Full Text] [Related]
32. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H Elife; 2020 Apr; 9():. PubMed ID: 32338605 [TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications. Haimei MA Clin Appl Thromb Hemost; 2020; 26():1076029620944497. PubMed ID: 32722927 [TBL] [Abstract][Full Text] [Related]
34. Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2? Bizzarri M; Laganà AS; Aragona D; Unfer V Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3426-3432. PubMed ID: 32271462 [TBL] [Abstract][Full Text] [Related]
35. The role of Neutrophil Extracellular Traps in Covid-19: Only an hypothesis or a potential new field of research? Mozzini C; Girelli D Thromb Res; 2020 Jul; 191():26-27. PubMed ID: 32360977 [No Abstract] [Full Text] [Related]
36. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19? Menegazzi M; Campagnari R; Bertoldi M; Crupi R; Di Paola R; Cuzzocrea S Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708322 [TBL] [Abstract][Full Text] [Related]
37. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. Ye Q; Wang B; Mao J J Infect; 2020 Jun; 80(6):607-613. PubMed ID: 32283152 [TBL] [Abstract][Full Text] [Related]
38. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19. Polansky H; Lori G J Evid Based Integr Med; 2020; 25():2515690X20932523. PubMed ID: 32551855 [TBL] [Abstract][Full Text] [Related]
39. Hematological findings and complications of COVID-19. Terpos E; Ntanasis-Stathopoulos I; Elalamy I; Kastritis E; Sergentanis TN; Politou M; Psaltopoulou T; Gerotziafas G; Dimopoulos MA Am J Hematol; 2020 Jul; 95(7):834-847. PubMed ID: 32282949 [TBL] [Abstract][Full Text] [Related]
40. Antineoplastic Effects of Ankaferd Hemostat. Malkan UY; Haznedaroglu IC Biomed Res Int; 2022; 2022():2665903. PubMed ID: 35958818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]